Current challenges in biotherapeutic particles manufacturing

Research output: Contribution to journalReview articlepeer-review

77 Citations (Scopus)


Introduction: The development of novel complex biotherapeutics led to new challenges in biopharmaceutical industry. The potential of these particles has been demonstrated by the approval of several products, in the different fields of gene therapy, oncolytic therapy, and tumor vaccines. However, their manufacturing still presents challenges related to the high dosages and purity required. Areas covered: The main challenges that biopharmaceutical industry faces today and the most recent developments in the manufacturing of different biotherapeutic particles are reported here. Several unit operations and downstream trains to purify virus, virus-like particles and extracellular vesicles are described. Innovations on the different purification steps are also highlighted with an eye on the implementation of continuous and integrated processes. Expert opinion: Manufacturing platforms that consist of a low number of unit operations, with higher-yielding processes and reduced costs will be highly appreciated by the industry. The pipeline of complex therapeutic particles is expanding and there is a clear need for advanced tools and manufacturing capacity. The use of single-use technologies, as well as continuous integrated operations, are gaining ground in the biopharmaceutical industry and should be supported by more accurate and faster analytical methods.

Original languageEnglish
JournalExpert Opinion on Biological Therapy
Publication statusAccepted/In press - 1 Jan 2019


  • Extracellular vesicles
  • gene-therapy
  • manufacturing
  • purification
  • vaccines; viral vectors
  • virus-like particles


Dive into the research topics of 'Current challenges in biotherapeutic particles manufacturing'. Together they form a unique fingerprint.

Cite this